How PRP Regenerative Injections Work: The Way Platelet Growth Factors Drive Tissue Healing
Last updated: 2026-06-11
PRP regenerative injections concentrate platelet growth factors from a patient's own blood and deliver them directly to damaged tissue, prompting the body to repair itself. Unlike treatments that simply block pain signals, PRP activates the body's own healing mechanisms — which is why it draws attention as a biological approach to chronic musculoskeletal injuries.
PRP (Platelet-Rich Plasma) begins with a healing system the body already has. When skin is cut, platelets rush in to stop bleeding and kick off tissue repair. Platelets carry a variety of proteins that detect damage and start the recovery process. PRP applies this principle clinically: blood is spun in a centrifuge to raise platelet concentration several times above baseline, and the resulting preparation is injected directly into the damaged area.
Activated platelets release several growth factors from storage compartments called alpha granules. PDGF signals repair cells to migrate to the wound site; TGF-β plays a role in collagen synthesis; VEGF supports the growth of new blood vessels, improving oxygen and nutrient delivery to damaged tissue. These growth factors work together to drive cells toward the injury, rebuild collagen, and structurally reconstruct the tissue. In a PRP environment, however, the role of each factor can vary depending on concentration, timing of release, and the condition of surrounding tissue. (Miron Richard J et al., 2024)
Using the patient's own blood also matters clinically. The risks of immune rejection and bloodborne infection transmission may be lower than with donor blood or certain synthetic materials — though procedure-related risks such as contamination during blood collection and processing, or infection at the injection site, are not eliminated entirely.
The key difference from corticosteroid injections lies in the mechanism. Corticosteroids strongly suppress inflammatory signals to produce rapid pain relief, but they do not directly repair the structural damage in injured tissue. PRP focuses on tissue reconstruction rather than inflammation control, making it a fundamentally different approach to the same pain complaint.
The Platelet Concentration Process: From Blood Draw to Injection
The procedure begins with a blood draw from a vein in the arm. The volume drawn depends on the kit and protocol used, but typically falls between 10 and 60 mL. The blood goes into a specialized kit and into a centrifuge; after about 10–15 minutes, the blood separates into layers, and the platelet-enriched upper plasma layer is collected. The entire process — from blood draw to injection — usually takes 30–45 minutes.
Centrifuge technique determines the characteristics of the final PRP preparation. LR-PRP (leukocyte-rich PRP), which retains white blood cells, has antimicrobial properties and tends to be used where infection is a concern or in certain cases of chronic tendinopathy (tendon degeneration). LP-PRP (leukocyte-poor PRP) causes less tissue irritation and is often preferred for cartilage lesions inside joints. Which type suits a given patient depends on the injury site and the nature of the lesion — and making that distinction is part of what separates informed injection practice from simply giving a shot.
The finished PRP is injected under ultrasound guidance. Placing an ultrasound probe on the skin displays the target structure — a tendon or a point inside a joint — in real time. The clinician confirms that the needle tip has reached the exact lesion site before injecting. (Masiello Francesca et al., 2023) This approach achieves better target accuracy than landmark-based injection and reduces the risk of injuring nearby nerves or blood vessels.
Ultrasound guidance is more than a safety measure. Tendinopathy lesions tend to cluster in specific areas of a tendon rather than spread evenly throughout it. Without precise localization, growth factors may never reach the tissue that needs them most — which is exactly why accurate placement matters for outcomes.
Indications: Musculoskeletal Conditions Where PRP May Be Considered
PRP may be appropriate for chronic tendinopathy and soft-tissue injuries caused by repetitive loading.
The most extensively studied indication is elbow tendinopathy. Lateral epicondylitis (tennis elbow) and medial epicondylitis (golfer's elbow) involve chronic degeneration of tendon tissue, and PRP is often considered when corticosteroid injections or physical therapy alone have not produced adequate recovery. Evidence has also been reported for pain reduction and functional improvement in rotator cuff tendinopathy and partial tears of the shoulder. (A Hamid Mohamad Shariff et al., 2021) Effect size and recovery patterns, however, vary between individuals.
Research is ongoing for chronic overuse injuries including plantar fasciitis, Achilles tendinopathy, and patellar tendinopathy (damage to the tendon at the front of the knee). Some reports suggest PRP may improve the cellular environment around articular cartilage damage, but this remains an active area of investigation that warrants careful judgment. (Masiello Francesca et al., 2023)
Contraindications are equally clear. Acute complete ruptures — where a tendon or muscle is fully torn — cannot be managed with PRP alone, and infectious lesions are a contraindication. Patients with platelet dysfunction or those taking anticoagulants may not be suitable candidates.
A pattern seen frequently in clinical practice: deciding on PRP based on symptoms alone, without imaging, often leads the treatment in the wrong direction. Ultrasound or MRI should confirm the location, extent, and chronicity of the injury before PRP is considered, identifying precisely which structure the injection must reach. That diagnostic process is the foundation of appropriate patient selection.
Recovery After the Procedure and How PRP Compares to Other Treatments
In the days immediately after the injection, the treated area may feel sore or uncomfortable. This is part of the tissue response triggered by growth factor release — the goal is not to suppress inflammation rapidly the way corticosteroids do. Some patients interpret this early discomfort as treatment failure, but clinical improvement has been reported to appear gradually, starting four to eight weeks after the procedure. The timing and degree of recovery vary between individuals.
Corticosteroid injections work faster for short-term pain suppression and remain a useful option during an acute, severely painful phase. Repeated use, however, has raised concerns in the clinical literature about progressive weakening of tendon tissue. PRP takes longer to show initial effects but targets structural change within the tissue itself over the medium to long term. (A Hamid Mohamad Shariff et al., 2021) Rather than ranking one approach above the other, what matters more is which treatment fits the patient's current stage and condition — and treatment response can vary depending on the extent of injury and the patient's overall health.
Some studies have examined combining PRP with other conservative treatments such as extracorporeal shock wave therapy (ESWT) or manual therapy. The evidence is not yet standardized enough to conclude that combination approaches consistently outperform PRP alone. ESWT induces a cellular response in tissue through mechanical stimulation, while PRP supplies biological growth factors directly — the two mechanisms target different points in the healing process. Manual therapy can complement PRP by supporting musculoskeletal alignment and functional recovery.
Several questions remain open. The optimal number of injections, the interval between sessions, and the concentration protocol differ across studies, and standardization is still in progress. (Masiello Francesca et al., 2023) Even patients with the same diagnosis may need different treatment plans depending on the severity of injury, how long it has been chronic, and their overall health. A realistic expectation is one that accounts for the time tissue needs to heal — not one built on the assumption that a single session will resolve everything.
For anyone considering PRP for the first time, the most important question is whether this approach suits the specific injury. PRP is considered when the injury site and lesion characteristics are a match, so diagnosis, imaging assessment, and the use of ultrasound guidance all form part of evaluating whether it is appropriate.
This content is provided for informational purposes only and may not apply to every individual situation. Please consult a specialist for an accurate diagnosis and personalized treatment plan.
References
- Miron Richard J, Gruber Reinhard, Farshidfar Nima (2024). Ten years of injectable platelet-rich fibrin. Periodontol 2000. PMID: 38037213
- Masiello Francesca, Pati Ilaria, Veropalumbo Eva (2023). Ultrasound-guided injection of platelet-rich plasma for tendinopathies: a systematic review and meta-analysis. Blood Transfus. PMID: 36346880
- A Hamid Mohamad Shariff, Sazlina Shariff Ghazali (2021). Platelet-rich plasma for rotator cuff tendinopathy: A systematic review and meta-analysis. PLoS One. PMID: 33970936
Frequently Asked Questions
How is PRP different from a corticosteroid (steroid) injection?
Corticosteroid injections rapidly suppress inflammation and excel at short-term pain relief, but repeated use has been associated with structural weakening of tendon tissue. PRP takes longer to produce noticeable effects; it works through growth factors to encourage damaged tissue to regenerate. The two treatments differ in purpose and timing, so the choice between them depends on the patient's stage of injury and overall condition.
How many PRP injections will I need?
The number of sessions depends on the condition being treated, the degree of injury, and how an individual's tissue responds. Clinical studies most commonly use protocols involving two to three injections spaced at set intervals. A typical approach is to assess progress over the four to eight weeks following the first injection before deciding whether additional sessions are warranted. Rather than following a fixed number, adjusting the plan based on observed treatment response is generally more appropriate.
What can I expect after the injection, and when can I return to normal activities?
Soreness or discomfort at the injection site for several days after the procedure is normal and reflects the tissue response to growth factor release. Most patients can return to everyday walking and light activity within a few days, but loading the treated area with strenuous exercise should be avoided for the period the clinician recommends. Clinical improvement is often reported to appear gradually from four to eight weeks onward.
Are there any medications I should stop before or after the procedure?
Non-steroidal anti-inflammatory drugs (NSAIDs) can affect platelet function, so patients are often advised to avoid them for a set period before and after the injection. Those taking anticoagulants or antiplatelet agents need to confirm ahead of time whether the procedure is appropriate for them and whether — and for how long — those medications should be paused. Bring a full list of current medications to the pre-procedure consultation.
What is the difference between LR-PRP and LP-PRP?
LR-PRP (leukocyte-rich PRP) retains white blood cells and has antimicrobial properties, making it a consideration where infection is a concern or in certain chronic tendinopathies. LP-PRP (leukocyte-poor PRP) causes relatively less tissue irritation and tends to be preferred for cartilage lesions inside joints. The appropriate type is determined by reviewing the lesion location, the degree of accompanying inflammation, and the individual patient's circumstances.